Nā huahana

Pahuhopu:JNK1 jnk2 NF- κ B

Haʻawina in vitro:ʻO ka isovitexin ke pale aku i ka LPS i hoʻokomo ʻia i ka pōʻino oxidative ma ke kāohi ʻana i ka hana ʻana o intracellular ROS, a hoʻonāwaliwali hoʻi i ka hopena o ka H2O2 ma ke ola o ke kelepona.Loaʻa iā LPS (2 μ Isovitexin (0-100 g / ml) μ G / ml) ʻaʻohe cytotoxicity i ka maka 264.7 mau cell, akā 200 μG / ml isovitexin i hōʻike i ka cytotoxicity nui.ʻO Isovitexin (25,50) μ G / ml) i kāohi i ka LPS i hoʻokomoʻia i ka TNF-α， Hoʻonui i nā pae o IL-6, iNOS a me COX-2.ʻO Isovitexin (25,50) μG / ml) ua kāohi pū ʻo I i ka 264.7 mau cell κ B α Phosphorylation a me ka degradation, i kūlike me ka hopena o JNK1 / 2 inhibitor [1].

Nā haʻawina ma vivo:ʻO ka isovitexin (50 a me 100 mg / kg, IP) i hoʻololi i nā loli histopathological liʻiliʻi i nā ʻāpana māmā a hoʻemi i ka nui o nā cell inflammatory i nā ʻiole i hoʻokomo ʻia e LPS.Heteroeosinophils (50 a me 100 mg / kg, IP) hoemi TNF e- α A me IL-6 hana, ROS hana, MPO a me MDA maʻiʻo, hoʻonui SOD a me GSH, a ua pale LPS i hoʻonāukiu a me ka oxidative stress i loko o LPS i hoʻokomo i nāʻiole Ali.A pale pono i ka hōʻike protein o iNOS a me COX-2 [1].ʻO Isovitexin (25,50, 100 mg / kg) i ho'ēmi i ka helu ola o ka LPS / D-gal i hoʻokomoʻia i kaʻeha ate i nāʻiole ma keʻano o ka hopena.Ua kāohi ʻo Isovitexin i ka NF-κ B a hoʻoponopono i ka LPS / D-gal i hoʻokomo ʻia i ka Nrf2 a me HO-1 i nā ʻiole [2].

ʻO ka hoʻokolohua kelepona:Ua hoʻoholo ʻia ke ola o ka cell e ka MTT assay.Ua hoʻopaʻa ʻia ʻo Raw 264.7 cell ma 96 well plates (1) × 104 cell / well) a me nā ʻano like ʻole o ka isovitexin (ka hopena hope: 0-200) μG / ml) a me LPS (2 μG / ml) no 24 mau hola.Eia kekahi, e hoʻohana i ka IV (25 a i ʻole 50 μG / ml) pretreated nā cell no 1 hola, a laila H 2O 2 (300) hoʻohui ʻia μ M）。 Ma hope o 24 mau hola, ua hoʻohui ʻia ka MTT (5 mg / ml) i ka nā pūnaewele a laila hoʻokomo ʻia no 4 mau hola [1].

Hoʻokolohua holoholona:ʻiole [1] i mea e hoʻokumu ai i ke kumu hoʻohālike Ali, ua māhele ʻia nā ʻiole i 6 mau pūʻulu: control (saline), isovitexin (100 mg / kg, hoʻoheheʻe ʻia i 0.5% DMSO), LPS wale nō (0.5 mg / kg, hoʻoheheʻe ʻia i ka saline. ), LPS (0.5 mg / kg) + isovitexin (50 a i ʻole 100 mg / kg) a me LPS (0.5 mg / kg) + dexamethasone (DEX, 5 mg / kg, hoʻoheheʻe ʻia i ka saline).Isovitexin a i ʻole DEX (5 mg / kg) i mālama ʻia ka isovitexin.Ma hope o ka ʻike ʻana i ka isovitexin a i ʻole DEX no 1 hola, ua hoʻomaʻamaʻa ʻia nā ʻiole me ka ether a ua lawelawe ʻia ʻo LPS intranasally (i) e hoʻoulu i ka hōʻeha ʻeha.Hoʻopau ʻia nā holoholona i nā hola 12 ma hope o ka hoʻokele LPS.No laila, ua hōʻiliʻili ʻia ka wai holoi holoi bronchoalveolar (BALF) a me nā ʻiʻo pūmāmā e ana i nā pae cytokine;Hanau ROS;Nā hana SOD, GSH, MDA a me MPO;A me ka ʻōlelo o COX-2, iNOS, HO-1 a me Nrf2 proteins [1].